OMEGA-3-ACID ETHYL ESTERS Drug Patent Profile
✉ Email this page to a colleague
When do Omega-3-acid Ethyl Esters patents expire, and when can generic versions of Omega-3-acid Ethyl Esters launch?
Omega-3-acid Ethyl Esters is a drug marketed by Amneal Pharms, Apotex, Ascent Pharms Inc, Bionpharma, Cspc-nbp Pharm, GLW, Mankind Pharma, Puracap Pharm Llc, Slayback Pharma Llc, Sofgen Pharms, Strides Pharma, Sun Pharm, and Zydus. and is included in fifteen NDAs.
The generic ingredient in OMEGA-3-ACID ETHYL ESTERS is omega-3-acid ethyl esters. There are thirteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the omega-3-acid ethyl esters profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Omega-3-acid Ethyl Esters
A generic version of OMEGA-3-ACID ETHYL ESTERS was approved as omega-3-acid ethyl esters by GLW on April 7th, 2014.
Summary for OMEGA-3-ACID ETHYL ESTERS
Recent Clinical Trials for OMEGA-3-ACID ETHYL ESTERS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sohag University | Phase 2/Phase 3 |
Aga Khan University Hospital, Pakistan | N/A |
Jinnah Postgraduate Medical Centre | N/A |
Pharmacology for OMEGA-3-ACID ETHYL ESTERS
Drug Class | Omega-3 Fatty Acid |
Paragraph IV (Patent) Challenges for OMEGA-3-ACID ETHYL ESTERS
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LOVAZA | Capsules | omega-3-acid ethyl esters | 1 g | 021654 | 3 | 2008-11-10 |